MK-8033 - CAS 1001917-37-8
Catalog number: 1001917-37-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C25H21N5O3S
Molecular Weight:
471.53
COA:
Inquire
Targets:
c-Met/HGFR
Description:
MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
Purity:
>98%
Synonyms:
MK-8033; MK 8033; MK8033
MSDS:
Inquire
1.Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.
Northrup AB1, Katcher MH, Altman MD, Chenard M, Daniels MH, Deshmukh SV, Falcone D, Guerin DJ, Hatch H, Li C, Lu W, Lutterbach B, Allison TJ, Patel SB, Reilly JF, Reutershan M, Rickert KW, Rosenstein C, Soisson SM, Szewczak AA, Walker D, Wilson K, Young J J Med Chem. 2013 Mar 28;56(6):2294-310. doi: 10.1021/jm301619u. Epub 2013 Mar 18.
This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of 11r was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related c-Met/HGFR Products


CAS 956905-27-4 PF-04217903

PF-04217903
(CAS: 956905-27-4)

PF-04136309 is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral adminis...

CAS 875337-44-3 MGCD-265

MGCD-265
(CAS: 875337-44-3)

MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively and also inhibits Ron a...

TAS-115
(CAS: 1190836-34-0)

This active molecular is a c-MET and VEGFR inhibitor which is selective and specific in vitro. In vivo studies, TAS-115 suppressed the progression of MET-inacti...

CAS 1174046-72-0 BMS-794833

BMS-794833
(CAS: 1174046-72-0)

BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM.

CAS 877399-52-5 Crizotinib

Crizotinib
(CAS: 877399-52-5)

Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.

Glesatinib hydrochloride
(CAS: 1123838-51-6)

The hydrochloride salt form of Glesatinib, an inhibitor of tyrosine kinase, could be effectively targeting tumors that are driving to grow through MET and AXL r...

CAS 1391426-24-6 Lys05

Lys05
(CAS: 1391426-24-6)

Lys05, a water-soluble salt of Lys01, is a selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively, resulting...

CAS 905854-02-6 Tivantinib

Tivantinib
(CAS: 905854-02-6)

Tivantinib (ARQ-197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-...

Chemical Structure

CAS 1001917-37-8 MK-8033

Quick Inquiry

Verification code

Featured Items